AGEN AGENUS INC

CIK 0001098972 50 ready 8-Ks latest August 6, 2026, 7:52 AM ET RSS · JSON

Activity: ELEVATED 3 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 50

Latest filing August 11, 2026, 4:30 PM ET

Top materiality 0.85

Event mix other_material ×17 · earnings ×15 · leadership ×7

Sentiment 16 pos · 7 neg · 27 neu

Latest earnings ▼ miss 2026-Q1

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for AGEN

Highest-materiality recent filing

Agenus raises $85M upfront (up to $340M) to fund registrational Phase 3 ROBBIN trial of BOT+BAL in MSS colon cancer

July 13, 2026, 6:30 AM ET other material materiality 0.85 positive item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Private placement of $85M upfront gross proceeds, plus up to $255M from warrant exercise; total up to $340M.
Proceeds to fund ROBBIN Phase 3 trial in neoadjuvant MSS colon cancer; expected runway through year-end 2031 if warrants exercised.

Read filing →

August 6, 2026, 7:52 AM ET earnings materiality 0.80 positive item 2.02 item 9.01

Agenus Q2 revenue $34.5M; $85M placement funds Phase 3 ROBBIN trial in MSS colon cancer

Q2 total revenue $34.5M (up from $25.7M YoY); pre-commercial product revenue $6.4M.
July 13, 2026, 6:30 AM ET other material materiality 0.85 positive item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Agenus raises $85M upfront (up to $340M) to fund registrational Phase 3 ROBBIN trial of BOT+BAL in MSS colon cancer

Private placement of $85M upfront gross proceeds, plus up to $255M from warrant exercise; total up to $340M.
May 11, 2026, 8:52 AM ET earnings materiality 0.85 positive item 2.02 item 9.01

Agenus Q1 net income $39.2M, revenue $33.7M; SEC closes investigation with no action

Net income of $39.2M vs loss of $26.4M in Q1 2025; total revenue $33.7M (+40% YoY).
March 26, 2026, 7:59 PM ET litigation materiality 0.65 positive item 8.01

Agenus wins dismissal of securities class action; court denies leave to amend

U.S. District Court for Massachusetts granted motion to dismiss entire securities class action against Agenus and four individual defendants.
March 16, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Agenus reports $4.2M initial BOT+BAL revenue; net loss narrows to $3.1M in FY2025

Pre-commercial product revenue of $4.2M from early access programs in France and paid NPP across 30+ countries.
January 16, 2026, 6:59 PM ET M&A materiality 0.85 positive item 2.01 item 9.01 item 3.02 item 7.01 ◈ Equity Issuances◈ M&A Transactions

Agenus closes $141M strategic collaboration with Zydus; sells manufacturing, issues equity, licenses BOT/BAL

Zydus pays $75M cash for Agenus' biologics manufacturing facilities in Emeryville and Berkeley, CA.
January 14, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

Agenus appoints CEO Garo Armen as interim CFO; names Austin Charette Principal Accounting Officer

Dr. Garo Armen, age 72, Chairman and CEO, appointed interim CFO and Principal Financial Officer effective Jan 8, 2026.
January 8, 2026, 6:59 PM ET other material materiality 0.65 negative item 1.01 item 3.03 ◈ Material Agreements

Agenus lowers warrant exercise price to $7.50; Ligand releases liens on assets

Modified warrant exercise price from $17.30 to $7.50 per share as part of Amendment Agreement with Ligand.
November 10, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Agenus reports Q3 net income on MiNK gain; France reimburses BOT/BAL access

France authorizes reimbursed compassionate access for BOT/BAL in refractory MSS mCRC; patients under treatment.
August 11, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Agenus Q2 net loss improves; Zydus deal adds $91M; BOT/BAL Phase 3 starts Q4 2025

Q2 revenue $25.7M; YTD net loss $56.4M vs $118.3M YoY; cash burn reduced to $45.8M from $76.4M.
June 4, 2025, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 7.01 item 9.01

Agenus sells manufacturing assets to Zydus for $75M upfront; license BOT/BAL in India

Asset sale of Emeryville/ Berkeley CA facilities for $75M at closing; up to $50M additional contingent payments.
May 12, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Agenus Q1 net loss $26.4M ($1.03/sh); cash burn reduced; BOT/BAL 100% pCR in dMMR CRC

Q1 2025 cash $18.5M (down from $40.4M Dec 2024); operating cash burn $25.6M vs $38.2M YoY.
March 11, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Agenus Q4 net loss $46.8M; targets annual cash burn of ~$50M by mid-2025

Q4 2024 net loss $46.8M ($2.04/share); full-year net loss $232.3M ($10.59/share).
February 26, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 2.03 item 3.02 item 9.01 ◈ Debt Financings

Agenus amends $10.5M notes, issues warrants at $3.25; maturity extended to July 2026

Extended maturity of $10.5M 2015 Notes from Feb 2025 to July 2026; interest rate raised from 8% to 9%.
February 10, 2025, 6:59 PM ET other materiality 0.65 neutral item 1.02

Agenus receives termination notice from Incyte for LAG-3/TIM-3 license; rights revert to Agenus

Incyte terminates License Agreement effective Feb 4, 2026; all rights to LAG-3 and TIM-3 revert to Agenus.
December 5, 2024, 6:59 PM ET other material materiality 0.75 negative item 2.05 item 9.01 ◈ Restructurings & Charges

Agenus strategic realignment: 60% annual cost cut, $100M cash burn target, workforce reduction

Agenus will reduce annual expenditures by 60% and target a cash burn of $100 million for fiscal year 2025.
November 27, 2024, 6:59 PM ET debt materiality 0.70 positive item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

Agenus secures $22M mortgage and announces realignment: 60% cost cut, FY25 cash burn ~$100M

$22M non-amortizing mortgage backed by Berkeley CMC facility and Vacaville land; net proceeds $20M after costs and reserve.
November 12, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Agenus Q3 2024 net loss $67.2M, cash $44.8M; BOT/BAL shows MSS CRC promise

Cash $44.8M at Sept 30, 2024 (vs $76.1M Dec 2023); raised $7.1M via ATM post-quarter.
August 8, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 5.02 item 8.01 item 9.01 ◈ executive_change

Agenus Q2 net loss $54.8M, advances BOT/BAL in CRC; appoints director; files ATM for up to 13.8M shares

Q2 net loss $54.8M, revenue $23.5M (incl $22.6M non-cash royalty); cash $93.7M at June 30 vs $76.1M Dec 31.
August 2, 2024, 7:59 PM ET other material materiality 0.85 negative item 1.02

BMS terminates AGEN1777 license; Agenus regains rights to TIGIT bispecific antibody

BMS voluntarily terminates AGEN1777 license agreement effective Jan 26, 2025, as part of strategic pipeline realignment.
June 17, 2024, 7:59 PM ET leadership materiality 0.65 positive item 5.02 item 9.01 ◈ executive_change

Agenus appoints Jennifer Buell to Board of Directors, stresses BOT/BAL BLA filing

Dr. Jennifer Buell appointed to Agenus Board effective June 11, 2024.
May 30, 2024, 7:59 PM ET M&A materiality 0.75 neutral item 2.01 ◈ M&A Transactions

Agenus closes $75M sale of royalty and milestone rights to Ligand

Received $75M on May 30, 2024, for sale of milestone and royalty rights to Ligand Pharmaceuticals.
May 7, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 7.01 item 9.01 ◈ Material Agreements

Agenus signs $100M royalty financing with Ligand; $75M upfront for BOT/BAL and partner programs

Ligand pays $75M at closing for 18.75% of royalties and 31.875% of milestones on six partnered oncology programs, plus 2.625% royalty on BOT/BAL net sales.
May 7, 2024, 7:59 PM ET other material materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Agenus reports Q1 net loss $63.5M; announces $100M royalty financing with Ligand

Net loss narrowed to $63.5M ($3.04/shr) from $70.9M ($4.31/shr) a year ago; revenue $28M.
March 14, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases

Agenus reports FY2023 net loss of $257M, revenue $156M; BOT/BAL data in CRC shows 24% ORR

FY2023 revenue $156M, net loss $257M ($0.69 EPS); Q4 revenue $84M, net loss $49M ($0.13 EPS).
February 15, 2024, 6:59 PM ET other material materiality 0.70 neutral item 7.01 item 9.01

Agenus proposes 1-for-20 reverse stock split to regain Nasdaq $1 compliance

Reverse stock split at 1:20 ratio proposed to lift share price above $1 Nasdaq minimum.
January 31, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01

Agenus receives $25M milestone payment from Bristol Myers Squibb for BMS-986442 trial progress

$25M payment received Jan 30, 2024, under global licensing agreement with BMS.
December 8, 2023, 6:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

Agenus receives Nasdaq deficiency notice for bid price below $1.00; has 180 days to cure

On Dec 4, 2023, Nasdaq notified Agenus that its common stock's closing bid price was below $1.00 for 31 consecutive business days.
November 7, 2023, 6:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases

Agenus Q3 net loss $64.5M; cash falls to $106.3M; BLA for botensilimab planned mid-2024

Net loss of $64.5M for Q3 2023, compared to $56.7M in Q3 2022; nine-month loss $208.9M.
August 23, 2023, 7:59 PM ET other material materiality 0.65 neutral item 2.05 item 9.01 ◈ Restructurings & Charges

Agenus cuts workforce 25%, pauses non-core programs to focus on BOT/BAL

Workforce reduction of ~25% expected to save $2.8M by year-end; severance cost ~$1.4M.
August 8, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Agenus Q2 2023 net loss $73.4M; bot/bal combo mOS 20.9 months in CRC, FDA Fast Track

Q2 revenue $25.3M, net loss $73.4M ($0.20 EPS); cash $157.6M at June 30, down from $193.4M at Dec 2022.
May 9, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Agenus Q1 net loss $70.9M; botensilimab combo shows 63% 12-month OS in colorectal cancer

Revenue $22.9M, net loss $70.9M ($0.22 EPS) vs loss $50.6M ($0.19 EPS) year ago.
March 30, 2023, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Agenus declares dividend of 5M shares of MiNK Therapeutics to shareholders

Record date April 17, 2023; payment no earlier than April 27 and no later than May 17, 2023.
March 14, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Agenus Q4 net loss $74M; botensilimab shows 23% ORR in MSS CRC, 50% in NSCLC

Q4 2022 revenue $28.4M, net loss $74.1M ($0.24/sh); FY22 revenue $98M, net loss $230.7M ($0.78/sh).
November 8, 2022, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Agenus reports Q3 net loss $56.7M, cash $218.2M; botensilimab Phase 2 trials initiated

Q3 2022 net loss $56.7M ($0.19/sh) vs prior-year net income; revenue $22.8M, down from $253M largely due to prior milestone.

Executive changes

Appointed

Marco Tullio Marcucci

Class II Director

AGEN · AGENUS INC

Effective: 2026-08-05
Filed: August 11, 2026, 4:30 PM ET

On August 5, 2026, the board of directors (the “Board”) of Agenus Inc., a Delaware corporation (the “Company”), increased the size of the Board from six (6) to seven (7) directors and appointed Marco Tullio Marcucci to fill the resulting vacancy as a Class II director, to serve until the Company’s 2029 annual meeting of stockholders and until his successor is duly elected and qualified, effective immediately.

Departed

Austin Charette

Principal Accounting Officer

AGEN · AGENUS INC

Effective: 2026-05-29
Filed: May 15, 2026, 4:08 PM ET

On May 12, 2026, Austin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer of Agenus Inc. (the "Company"), informed the Company he will be resigning effective May 29, 2026.

Departed

Ulf Wiinberg

Director

AGEN · AGENUS INC

Effective: 2024-11-05
Filed: November 5, 2024, 6:59 PM ET

On October 30, 2024, Ulf Wiinberg resigned as a director at Agenus Inc. (the “Company”), effective as of 5:00 p.m. Eastern Time on November 5, 2024.

Appointed

Thomas L. Harrison

Class III director

AGEN · AGENUS INC

Effective: 2024-08-07
Filed: August 8, 2024, 7:59 PM ET

On August 7, 2024, the Board of Directors (the “Board”) of Agenus elected Thomas L. Harrison to become a Class III director of Agenus with an initial term that expires at Agenus’s annual meeting of stockholders in 2027.

Appointed

Jennifer Buell

Director

AGEN · AGENUS INC

Effective: 2024-06-11
Filed: June 17, 2024, 7:59 PM ET

Dr. Jennifer Buell was appointed to the Board of Directors of Agenus Inc. (Agenus) on June 11, 2024, effective immediately.

Departed

Wadih Jordan

Director

AGEN · AGENUS INC

Effective: 2022-12-31
Filed: December 23, 2022, 6:59 PM ET

On December 21, 2022, Wadih Jordan sent notice of his resignation as a director at Agenus Inc. (the "Company"), effective as of December 31, 2022.

Departed

Jennifer Buell

President and Chief Operating Officer

AGEN · AGENUS INC

Effective: 2021-12-31
Filed: January 6, 2022, 6:59 PM ET

Effective December 31, 2021, Dr. Jennifer Buell resigned as Agenus Inc.’s (the “Company”) President and Chief Operating Officer to become the President and Chief Executive Officer of MiNK Therapeutics, Inc. (“MiNK”), a subsidiary of the Company.

Departed

Adam F. Krauss

Chief Legal Officer and Chief Compliance Officer

AGEN · AGENUS INC

Effective: 2021-07-30
Filed: July 26, 2021, 7:59 PM ET

On July 20, 2021, Adam F. Krauss, Chief Legal Officer and Chief Compliance Officer of Agenus Inc. provided notice that he will be stepping down from his role effective July 30, 2021.

Earnings & guidance

2026-Q1 EPS reported $1.02 vs consensus $2.14 ▼ miss (-52.4%) filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

16 positive 7 negative 27 neutral

source · AGEN on sec.gov